Abstract:Background: Time-to-event (TTE) endpoints are evaluated as the primary endpoint in single-arm clinical trials; however, limited options are available in statistical software for sample size calculation. In single-arm trials with TTE endpoints, the non-parametric log-rank test is commonly used. Parametric options for single-arm design assume survival times follow exponential distribution or Weibull distribution. Methods: The exponential- or Weibull-distributed survival time assumption does not always reflect hazard pattern of real-life diseases. We therefore propose gamma distribution as an alternative parametric option for designing single-arm studies with TTE endpoints. We outline a sample size calculation approach using gamma distribution with a known shape parameter and explain how to extract the gamma shape estimate from previously published resources. In addition, we conduct simulations to assess the accuracy of the extracted gamma shape parameter and to explore the impact on sample size calculation when survival time distribution is misspecified. Results: Our simulations show that if a previously published study (sample sizes ≥ 60 and censoring proportions ≤ 20 %) reported median and inter-quartile range of survival time, we can obtain a reasonably accurate gamma shape estimate, and use it to design new studies. When true survival time is Weibull-distributed, sample size calculation could be underestimated or overestimated depending on the hazard shape. Conclusions: We show how to use gamma distribution in designing a single-arm trial, thereby offering more options beyond the exponential and Weibull. We provide a simulation-based assessment to ensure an accurate estimation of the gamma shape and recommend caution to avoid misspecification of the underlying distribution.

Sample size estimation for survival analysis in single-arm trials

Sample Size Estimation for Stratified Cluster Randomization Trial with Survival Endpoint.

Sample size estimation for cancer randomized trials in the presence of heterogeneous populations

Sample size calculation for studies with grouped survival data

Power and Sample Size for Dose-Finding Studies with Survival Endpoints under Model Uncertainty.

Analysis and sample size calculation within the responder stratified exponential survival model

A Practical Simulation Method to Calculate Sample Size of Group Sequential Trials for Time-to-Event Data under Exponential and Weibull Distribution

Sample Size Re-Estimation Without Un-Blinding for Time-to-event Outcomes in Oncology Clinical Trials

Sample size determination for semiparametric analysis of current status data

Strategies for power calculations in predictive biomarker studies in survival data

On sample size determination for restricted mean survival time-based tests in randomized clinical trials

Simplification or simulation: Power calculation in clinical trials

Sample size estimation for modified Poisson analysis of cluster randomized trials with a binary outcome

Sample Size Estimation in Clinical Research

Sample size considerations for single-arm clinical trials with time-to-event endpoint using the gamma distribution

Sample size calculation of clinical trials in geriatric medicine

Sample size for a non-inferiority clinical trial with time-to-event data in the presence of competing risks

BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS

Sample size calculation for two‐arm trials with time‐to‐event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions

The Conditional Power of Interim Analysis and Sample Size Re-estimation

Power and sample size calculation for the additive hazard model